Delay Of 2024 Financial Report Publication: An Update From Valerio Therapeutics S.A.

Natalie Brooks

3 min read

Post on May 17, 2025

4.7

Share

Reasons for the Delay in Publication of the Valerio Therapeutics Financial Report

The delay in the publication of the Valerio Therapeutics 2024 financial report is due to a confluence of factors requiring additional time for thorough completion. We are committed to ensuring the accuracy and reliability of the information presented, and this necessitates a more considered approach than initially anticipated.

• Unexpected complexities in the audit process related to the recent acquisition of NovaPharma: The integration of NovaPharma's financial data into our consolidated report has proven more complex than initially projected, requiring additional time for thorough reconciliation and audit review. This includes aligning accounting practices and ensuring compliance with relevant international financial reporting standards. This contributed significantly to the Valerio Therapeutics reporting delay.

• Need for additional time to fully consolidate financial data from various international operations: Valerio Therapeutics operates across multiple international markets. Consolidating financial data from these diverse regions, considering varying accounting standards and exchange rate fluctuations, requires meticulous attention to detail and has necessitated a prolonged consolidation process. This impacted the timely release of the Valerio Therapeutics 2024 financial statement.

• Internal restructuring impacting financial reporting procedures: Recent internal restructuring initiatives, designed to streamline operations and enhance efficiency, have indirectly impacted our financial reporting processes. These changes require recalibration and adjustments to ensure seamless integration with our existing systems. This contributed to the Valerio Therapeutics financial report delay.

• Minor delay caused by external factors beyond the company's control: A minor, unforeseen delay from our external auditor, KPMG, related to their internal resource allocation, has further impacted the timeline for completing the audit and finalizing the report.

Impact of the Delay on Investors and Stakeholders

We understand that the Valerio Therapeutics 2024 financial statement delay may cause concern amongst our investors and stakeholders. We want to emphasize our unwavering commitment to transparency and providing accurate financial information.

• Reiteration of Commitment to Transparency: Valerio Therapeutics remains steadfast in its commitment to providing timely and accurate financial information to all stakeholders. The delay is a result of our dedication to ensuring the highest standards of financial reporting.

• Potential Impact on Shareholder Meetings: The delay may necessitate a slight postponement of the planned shareholder meeting. We will communicate the revised date promptly via official channels once finalized.

• Minimizing Disruption: We are actively working to minimize any disruption caused by the delay and are implementing measures to ensure a smooth and efficient release of the financial report as soon as possible. We are prioritizing open communication with investors and stakeholders to address any questions or concerns.

Revised Timeline for Publication of the Valerio Therapeutics Financial Report

We anticipate releasing the Valerio Therapeutics 2024 financial report by October 26, 2024. This revised date allows us sufficient time to address all outstanding issues and ensure the accuracy of the information presented.

• New Expected Release Date: October 26, 2024.

• Communication Plan: We will provide updates via our investor relations website and will send email notifications to registered shareholders.

• Contact Information: For any inquiries, please contact us at [email protected].

Conclusion

The delay in the publication of the Valerio Therapeutics 2024 financial report is primarily due to the complexities of integrating data from our recent acquisition, the need for thorough consolidation of international financial data, internal restructuring impacts, and a minor external auditor delay. We understand the importance of timely reporting and apologize for any inconvenience this delay may cause. We are committed to transparency and providing accurate financial information. The revised publication date is October 26, 2024. Stay informed by visiting the Valerio Therapeutics investor relations website for updates on the Valerio Therapeutics financial report and subscribe to email alerts for timely updates regarding the Valerio Therapeutics 2024 financial report delay and its resolution. Follow our updates!